Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Who Can Use MDR's Four-Year Derogation Extension? Notified Bodies Try To Clarify

Executive Summary

Many companies are pinning hopes on being able to use the EU Medical Device Regulation's four-year extension period for products CE marked under the current directives. But with a lack of clarity from the policymakers so far, TEAM-NB has stepped in.

You may also be interested in...

Stop The Clock: MedTech Europe Says IVDR, MDR Deadlines Won't Work

Given the slow progress in implementing the new EU medtech regulations, industry group MedTech Europe is seeking urgent talks with the EU institutions and affected stakeholders to delay deadlines.

One-Third Of SMEs To Change Notified Body; Half Believe EU MDR Deadline Extension Likely, Survey Finds

If the findings of a Swiss survey of smaller companies represent the picture around the EU in general, companies are ill-prepared for the new Medical Device Regulation, confused, and far from convinced of its value.

New Reasons Not To Use EU MDR's Four-Year Extension, But Comply Earlier Or Retire Products Instead

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts